Antoinette Wozniak - Concepedia

Author

Antoinette Wozniak

Wayne State University

Also Known As

Antoinette Wozniak

Publications

636

Citations

H-Index

Concepts

All Affiliations

Wayne State University The Barbara Ann Karmanos Cancer Institute Pfizer (United States)

About

Antoinette Wozniak is an author at Wayne State University specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	426
2	Pharmacology	6	6	292
3	Cancer Therapeutics	2	2	67
4	Health Sciences	1	1	35
5	Cell Biology	1	1	35

Antoinette Wozniak

Publications

574

Citations

H-Index

Page 1

	Year	Citations
Chronic Oral Administration of CI-994: A Phase I Study Sucharu Prakash, Brenda J. Foster, Mark Meyer, Investigational New Drugs MedicineChronic Oral AdministrationOral Cavity	2001	134
Activity of flavone acetic acid (NSC-347512) against solid tumors of mice Thomas H. Corbett, Marie-Christine Bissery, Antoinette Wozniak, Investigational New Drugs Flavone Acetic AcidSolid TumorsMedicineOncogenic AgentPharmacology	1986	122
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105 Alexander Drilon, Siqing Fu, Manish R. Patel, Cancer Discovery	2018	112
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors Patricia LoRusso, Shirish M. Gadgeel, Antoinette Wozniak, Investigational New Drugs Drug TargetingAngiogenesisSolid TumorsMedicinePharmacology	2008	70
Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation Nadine Abdallah, Misako Nagasaka, Eman Abdulfatah, Lung Cancer Targets and Therapy	2018	36
Tumor Models and the Discovery and Secondary Evaluation of Solid Tumor Active Agents Thomas H. Corbett, Fred Valeriote, Patricia LoRusso, International Journal of Pharmacognosy Tumor BiologyTumor HeterogeneityTheranosticsTumor ModelsAnti-cancer Agent	1995	35
A Phase I Trial of Daily Oral 4′-N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies Joseph P. Eder, Rocio García‐Carbonero, Jeffrey W. Clark, Investigational New Drugs OncologyProtracted Continuous InfusionMedicineAdvanced Solid MalignanciesPharmacotherapy	2004	32
Phase I trial of Adozelesin using the treatment schedule of daily × 5 every 3 weeks Brenda J. Foster, Patricia LoRusso, Elizabeth Poplin, Investigational New Drugs MedicinePharmacotherapyPharmacologyTreatment Schedule	1995	23
Phase I Clinical Trial of 5-Fluoro-Pyrimidinone (5FP), an Oral Prodrug of 5-Fluorouracil (5FU) Patricia LoRusso, Sucharu Prakash, Antoinette Wozniak, Investigational New Drugs Medicinal ChemistryPharmaceutical SciencePharmacologyOral ProdrugClinical Pharmacology	2002	10

Page 1